Engineering of major house dust mite allergens der p 1 and der p 2 for allergen-specific immunotherapy

Clinical and Experimental Allergy

Volumn 39, Issue 7, 2009, Pages 1088-1098

  Asturias, J A ^a   Ibarrola, I ^a   Arilla, M C ^a   Vidal, C ^b   Ferrer, A ^c   Gamboa, P M ^d   Vinuela J ^b   Sanz, M L ^e   Andreu, C ^c   Martinez A ^a  

^a Research and Development Department   (Spain)

^b UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^c HOSPITAL VEGA BAJA   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Blocking antibodies; Genetic engineering; House dust mite allergy; Hybrid proteins; IgE epitope; Recombinant hypoallergens

Indexed keywords

ALUMINUM HYDROXIDE; DER P 1 PROTEIN; DER P 2 PROTEIN; HOUSE DUST ALLERGEN; HYBRID PROTEIN; IMMUNOGLOBULIN E; QM1 PROTEIN; QM2 PROTEIN; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGENICITY; ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DRUG POTENCY; FEMALE; HOUSE DUST ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRICK TEST; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PURIFICATION; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; CELL PROLIFERATION; CLONING, MOLECULAR; FEMALE; GENETIC ENGINEERING; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SKIN TESTS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 66749152698     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03264.x     Document Type: Article

References (52)

1. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007 119 : 780 9.
2. Westritschnig K, Valenta R. Can we genetically engineer safer and more effective immunotherapy reagents? Curr Opin Allergy Clin Immunol 2003 3 : 495 500. (Pubitemid 39149564)
3. van Ree R, Antonicelli L, Akkerdaas JH, Garritani MS, Aalberse RC, Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy 1996 51 : 108 13.
4. Valenta R, Linhart B. Molecular design of allergy vaccines. Curr Opin Immunol 2005 17 : 1 10.
5. Ferreira F, Briza P, Inführ D et al. Modified recombinant allergens for safer immunotherapy. Inflam Allergy Drug Targets 2006 5 : 5 14. (Pubitemid 43796677)
6. Akdis CA, Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 2000 121 : 261 9.
7. Moverate R. Immunological mechanisms of specific immunotherapy with pollen vaccines: implications for diagnostics and the development of improved vaccination strategies. Expert Rev 2003 2 : 85 97.
8. Boulet LP, Turcotte H, Laprise C. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma. Clin Exp Allergy 1997 27 : 52 9.
9. Griffin P, Ford AW, Alterman L. Allergenic and antigenic relationship between three species of storage mite and the house dust mite, Dermatophagoides pteronyssinus. J Allergy Clin Immunol 1989 84 : 108 17.
10. Van Der Zee JS, Van Swieten P, Jansen HM, Aalberse RC. Skin tests and histamine release with P1-depleted Dermatophagoides pteronyssinus body extracts and purified P1. J Allergy Clin Immunol 1988 81 : 884 95.
11. Meyer CH, Bond JF, Chen MS, Kasaian MT. Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, Dermatophagoides pteronyssinus. Clin Exp Allergy 1994 24 : 1041 8.
12. Pittner G, Vrtala S, Thomas WR et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004 34 : 597 603. (Pubitemid 38534892)
13. Hales BJ, Martín AC, Pearce LJ et al. IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol 2006 118 : 361 7.
14. de Halleux S, Stura E, VanderElst L, Carlier V, Jacquemin M, Saint-Remy JM. Three-dimensional structure and IgE-binding properties of mature fully active Der p 1, a clinically relevant major allergen. J Allergy Clin Immunol 2006 117 : 571 6.
15. Meno K, Thorsted PB, Ipsen H et al. The crystal structure of recombinant proDer P 1, a major house dust mite proteolytic allergen. J Immunol 2005 175 : 3835 45.
16. Kircher MF, Haeusler T, Nickel R, Lamb JR, Renz H, Beyer K. Vb 18.1 and Va 2.3+ T-cell subsets are associated with house dust mite allergy in human subjects. J Allergy Clin Immunol 2002 109 : 517 23.
17. Greene WK, Thomas WR. IgE binding structures of the major house dust mite allergen Der p I. Mol Immunol 1992 29 : 257 62.
18. Collins SP, Ball G, Vonarx E et al. Absence of continuous epitopes in the house dust mite major allergens Der p I from Dermatophagoides pteronyssinus and Der f I from Dermatophagoides farinae. Clin Exp Allergy 1996 26 : 36 42. (Pubitemid 26036133)
19. Chapman MD, Wünschmann S, Pomés A. Proteases as Th2 adjuvants. Curr Allergy Asthma Rep 2007 7 : 363 7.
20. Derewenda U, Li J, Derewenda Z et al. The crystal structure of a major dust mite allergen Der p 2, and its biological implications. J Mol Biol 2002 318 : 189 97.
21. Szalai K, Fuhrmann J, Pavkov T et al. Mimotopes identify conformational B-cell epitopes on the two major house dust mite allergens Der p 1 and Der p 2. Mol Immunol 2008 45 : 1308 17.
22. Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002 129 : 1 18. (Pubitemid 35316844)
23. O'Heir RE, Verhoef A, Panagiotopolou E et al. Analysis of human T cell responses to the group II allergen of Dermatophagoides species: localization of major antigenic sites. J Allergy Clin Immunol 1993 92 : 105 13.
24. Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004 134 : 324 31.
25. Yasueda H, Mita H, Yui Y, Shida T. Comparative analysis of physicochemical and immunochemical properties of the two major allergens from Dermatophagoides pteronyssinus and the corresponding allergens from Dermatophagoides farinae. Int Arch Allergy Appl Immunol 1989 88 : 402 7.
26. Way M, Pope B, Gooch J, Hawkins M, Weeds AG. Identification of a region in segment 1 of gelsolin critical for actin binding. EMBO J 1990 9 : 4103 9.
27. Arilla MC, González-Rioja R, Ibarrola I et al. A sensitive monoclonal antibody-based enzyme-linked immunosorbent assay to quantify Parietaria judaica major allergens, Par j 1 and Par j 2. Clin Exp Allergy 2006 36 : 87 93.
28. Asturias JA, Ibarrola I, Eraso E, Arilla MC, Martínez A. The major Platanus acerifolia pollen allergen Pla a 1 has sequence homology to invertase inhibitors. Clin Exp Allergy 2003 33 : 978 85.
29. González-Rioja R, Ibarrola I, Arilla MC et al. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. J Allergy Clin Immunol 2007 120 : 602 9.
30. Moverate R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002 57 : 423 30.
31. Ball T, Sperr WR, Valent P. Introduction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999 29 : 2026 36.
32. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998 53 : 1 42. (Pubitemid 28346358)
33. Battista Pajno G, La Grutta S, Barberio G, Canonica GW, Passalacqua G. Harmful effect of immunotherapy in children with combined snail and mite allergy. J Allergy Clin Immunol 2002 109 : 627 9.
34. Valenta R, Kraft D. Recombinant allergens: from production and characterization to diagnosis, treatment, and prevention of allergy. Methods 2004 32 : 207 8.
35. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007 118 : 826 30.
36. Weghofer M, Thomas WR, Pittner G, Horak F, Valenta R, Vrtala S. Comparison of purified Dermatophagoides pteronyssinus allergens and extract by two-dimensional immunoblotting and quantitative immunoglobulin E inhibitions. Clin Exp Allergy 2005 35 : 1384 91.
37. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004 101 : 14677 82.
38. Pauli G, Malling H, Rak S et al. Subcutaneous immunotherapy with recombinant Bet v 1 in birch allergy: clinical and immunological effects. Allergy 2007 62 (Suppl 83) : 256.
39. Hakkaart GAJ, Aalberse RC, vanRee R. Epitope mapping of the house-dust-mite allergen Der p 2 by means of site-directed mutagenesis. Allergy 1998 53 : 165 72.
40. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996 33 : 399 405. (Pubitemid 26191484)
41. Takai T, Yokota T, Yasue M et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997 15 : 754 8.
42. Korematsu S, Tanaka Y, Hosoi S et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J Immunol 2000 165 : 2895 902.
43. Georgiou G, Valax P. Expression of correctly folded proteins in Escherichia coli. Curr Opin Biotechnol 1996 7 : 190 7.
44. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB J 2001 15 : 2045 7.
45. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003 132 : 13 24. (Pubitemid 37256012)
46. Mothes-Luksch N, Stumvoll S, Linhart B et al. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as mosaic protein. J Immunol 2008 181 : 4864 73.
47. Chen K-W, Fuchs G, Sonneck K et al. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite, by genetic engineering. Mol Immunol 2008 45 : 2486 98.
48. Chapman MD, Heymann PW, Platts-Mills TAE. Epitope mapping of two major inhalant allergens, Der p 1 and Der p 2, from mites of the genus Dermatophagoides. J Immunol 1987 139 : 1479 84.
49. Linhart B, Jahn-Schmid B, Verdino P et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002 16 : 1301 3.
50. Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. An hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, phl p 2 and Phl p 6. Biol Chem 2008 389 : 925 33.
51. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005 116 : 608 13.
52. Cromwell O, Fiebig H, Suck R et al. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin N Am 2006 26 : 261 81.